Valion Bio’s 56% Slide: Why Micro‑Cap Bio‑Tech Stocks Must Be ScrutinizedValion Bio’s steep 55% slide shows why micro‑cap biotech stocks need clear product, funding and investor confidence.VALION BIO INCUnited States Health Care Pharmaceuticals, Biotechnology & Life Sciences AI generated Vanessa Liu 23/10/2026, 07:29 3 minutes to read
